"We are encouraged by the tolerability and clear activity of PSMA ADC in this heavily pre-treated population," said Hagop Youssoufian, M.D., Executive Vice President, Research and Development. "For example, reductions in CTC's of more than 50% were seen in over 70% of patients treated."
Dr Youssoufian also said, "we look forward to the upcoming data in the less clinically advanced chemo naive setting, where our ADC technology may provide an even greater clinical benefit to men with prostate cancer."
"I've been encouraged by the response seen to date in our patients," said Daniel Petrylak, M.D., Professor of Medical Oncology at Yale Cancer Center, Clinical Research Program Leader for the Prostate and Urologic Cancers Program at Smilow Cancer Hospital at Yale-New Haven, and lead investigator on the trial. "I believe that the 2.3 mg/kg dose has been well tolerated," added Dr. Petrylak.
"We have long held the belief that PSMA expression would correlate with response, and were pleased to see that correlation in this trial. I was also pleased that another biomarker that measures low neuroendocrine disease also correlates and offers the ability to identify responders in this trial through the use of a simple blood test," said Mark R. Baker, CEO of Progenics.